June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Effectiveness and cost-effectiveness of a new botulinum toxin treatment for benign essential blepharospasm
Author Affiliations & Notes
  • Alberto Chierigo
    Ophthalmology, Universita degli Studi di Genova, Genova, Liguria, Italy
  • Chiara Del Noce
    Ophthalmology, Universita degli Studi di Genova, Genova, Liguria, Italy
  • Aldo Vagge
    Ophthalmology, Universita degli Studi di Genova, Genova, Liguria, Italy
  • Carlo Traverso
    Ophthalmology, Universita degli Studi di Genova, Genova, Liguria, Italy
  • Footnotes
    Commercial Relationships   Alberto Chierigo None; Chiara Del Noce None; Aldo Vagge None; Carlo Traverso None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4077. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alberto Chierigo, Chiara Del Noce, Aldo Vagge, Carlo Traverso; Effectiveness and cost-effectiveness of a new botulinum toxin treatment for benign essential blepharospasm. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4077.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Currently, there is still no consensus on both dose and pattern of botulinum toxin injections in the treatment of benign essential blepharospasm (BEB). We compared the effectiveness and cost-effectiveness of our standard treatment pattern versus a new one, which spares the injections in the inferior pretarsal orbicularis oculi muscle.

Methods : In this prospective, monocentric study conducted between September and November 2022 52 adult patients with BEB were visited before (T0) and 2 months after (T2) the treatment. 25 patients received the standard treatment pattern (19 injections) and 27 the new one (17 injections). We used validated questionnaires to query patients on disease severity, frequency of symptoms, quality of life, pain perception and satisfaction with our care. We also compared the costs of our new procedure vs the standard one. Two-tailed t-test was used to test for differences in mean score changes from T0 to T2 in the standard vs new treatment. The study was approved by our local ethical board committee.

Results : No statistically significant differences (all p>0.05) were recorded between T0 and T2 between the standard vs the new treatment groups for disease severity (1.35 ± 0.89 vs 1.08 ± 0.76), frequency of symptoms (1.23 ± 0.71 vs 0.96 ± 0.45), quality of life (3.56 ± 2.18 vs 3.43 ± 5.33), and satisfaction with care (31.6 ± 0.7 vs 31.3 ± 1.3).
On the contrary, statistically significant differences were recorded in mean rating for visual analogue (7.08 ± 1.29 vs 5.03 ± 1.94), verbal (2.2 ± 0.7 vs 1.52 ± 0.58), and numerical (6.96 ± 1.39 vs 4.88 ± 2.02) scales of pain perception for the standard vs new treatments, respectively (all p<0.001).
Finally, costs analysis showed that our new treatment pattern saved 23.60 euros for each session, a 21.05% reduction in price.

Conclusions : Our new treatment pattern maintained a similar efficacy to the standard one in terms of disease control; however, the new treatment had a better tolerability and cost-effectiveness profile.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×